Nanexa AB (40M) AI Stock Analysis

Nanexa AB

(Frankfurt:40M)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

PharmaShell platformThe PharmaShell platform addresses an important pharmaceutical development need by targeting sustained drug release and more convenient dosing. If technical development succeeds, this capability could support differentiated injectable medicines and create durable partnering opportunities across multiple drug programs.

Negative Factors

Sharp revenue declineThe sharp TTM revenue contraction indicates that commercial or development income has not yet developed into a stable growth trajectory. Continued volatility makes planning more difficult and weakens confidence that the platform is currently translating into scalable operating revenue.

Nanexa AB (40M) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 179.86M
Dividend Yield: ―
Average Volume (3M): 14.91K
Price to Earnings (P/E): -76.5
Beta (1Y): 1.28
Revenue Growth: 112.36%
EPS Growth: 34.04%
Country: Germany
Employees: 17
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Nanexa AB Business Overview & Revenue Model

Company Description

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug...

Nanexa AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:40M against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	80Outperform	SEK 40.76B	59.09	15.54%	―	<0.01%	-6.75%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:NICA	46Neutral	SEK 54.25M	0.48	23.67%	―	163.58%	―
SE:ENZY	44Neutral	SEK 551.01M	-12.24	―	―	-2.36%	23.44%
SE:SPAGO	43Neutral	SEK 32.09M	-0.85	-106.23%	―	-97.37%	25.28%
SE:XSPRAY	41Neutral	SEK 559.52M	-3.06	-26.00%	―	―	44.46%

* Healthcare Sector Average

Performance Comparison

DE:40M and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:40M	Nanexa AB	0.92	0.77	531.72%
SE:CAMX	Camurus AB	673.00	46.00	7.34%
SE:NICA	Nanologica AB	0.17	-1.10	-86.94%
SE:XSPRAY	Xspray Pharma AB	11.80	-12.80	-52.04%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.11	-72.79%
SE:ENZY	Enzymatica AB	2.27	0.32	16.41%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Nanexa AB AI Stock Analysis